Search clinical trials for: Methotrexate inadequate responders

Total 2687 results

NYU Langone Health
Arthritis Foundation

Recruiting

Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders (EASi-RAIR)

Rheumatoid Arthritis

United States
Galapagos NV

Completed

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1) (DARWIN1)

Rheumatoid Arthritis

France, Spain, New Zealand, Belgium, Israel, Chile, United States, Colombia, Germany, Australia, Poland, Hungary, Russian Federation, Mexico, Argentina, Bulgaria, Czechia, Guatemala, Latvia, Moldova, Republic of, Ukraine, Austria
Novo Nordisk A/S

Terminated

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Inflammation | Rheumatoid Arthritis

United States, Mexico, Russian Federation, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Poland, Ukraine, Hungary
SynAct Pharma Aps
NBCD A/S

Recruiting

A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (RESOLVE)

Rheumatoid Arthritis

Moldova, Republic of
AbbVie

Recruiting

An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab (CAN UpTIMISE)

Atopic Dermatitis

Canada
Atsushi Kawakami
Gilead Sciences

Recruiting

Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate (TRANSFORM)

Rheumatoid Arthritis | Biomarker | JAK Inhibitor | Musculoskeletal Ultrasound | IL-6 Inhibitor

Japan
Lille Catholic University

Recruiting

Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders (SUNSTAR)

Arthritis, Rheumatoid

France
Astellas Pharma China, Inc.

Completed

A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)

Rheumatoid Arthritis (RA)

China, Korea, Republic of, Taiwan
National Institute of Allergy and Infectious Diseases...
Rho Federal Systems Division, Inc.; Autoimmunity Centers of Excellence

Completed

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Systemic Lupus Erythematosus (SLE) | Multiple Sclerosis (MS) | Rheumatoid Arthritis (RA) | Juvenile Dermatomyositis (JDM) | Juvenile Idiopathic Arthritis (JIA) | Pemphigus Vulgaris | Systemic Sclerosis (SSc) | Pediatric SLE | Pediatric-Onset Multiple Sclerosis (POMS)

United States
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (contRAst 1)

Arthritis, Rheumatoid

Hungary, Poland, Malaysia, Spain, China, Russian Federation, India, United Kingdom, Italy, Serbia
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy

Healthy | Arthritis, Rheumatoid

Germany, Netherlands, New Zealand, Poland, Spain, Czechia
Kiniksa Pharmaceuticals, Ltd.

Active, not recruiting

Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Arthritis, Rheumatoid

United States, Poland, Hungary, Georgia, Czechia, South Africa, Bulgaria
AbbVie

Completed

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

Rheumatoid Arthritis

United States, Argentina, Australia, Austria, Belgium, Bulgaria, Chile, Czechia, Estonia, Greece, Hungary, Israel, Italy, Japan, Mexico, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Serbia, South Africa, Spain, Turkey, Uk...
Hoffmann-La Roche

Completed

An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy

Rheumatoid Arthritis

China
Bristol-Myers Squibb

Active, not recruiting

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Rheumatoid Arthritis

Italy, United States, Germany, Argentina, Australia, Czechia, France, Japan, Mexico, Poland, Spain, Switzerland, Taiwan, United Kingdom
RemeGen Co., Ltd.

Completed

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

Moderate and Severe RheumatoId Arthritis

China
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)

Rheumatoid Arthritis

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, ... and more
Pfizer

Completed

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Rheumatoid Arthritis

Czechia, Hungary, Spain, Poland, Canada, Bulgaria, Chile, Georgia, Slovakia, Ukraine
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Rheumatoid Arthritis

China
Galapagos NV
Gilead Sciences

Completed

Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients (DARWIN3)

Rheumatoid Arthritis

New Zealand, Belgium, Israel, Chile, Argentina, Colombia, Spain, Australia, Latvia, Poland, Russian Federation, United States, Bulgaria, Czechia, France, Germany, Guatemala, Hungary, Mexico, Moldova, Republic of, Romania, Ukraine
Galapagos NV

Completed

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate (LADYBUG)

Rheumatoid Arthritis

Ukraine, Georgia, Bulgaria, Poland
Amgen

Completed

Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate

Rheumatoid Arthritis
Eisai Co., Ltd.
FUJIFILM Toyama Chemical Co., Ltd.

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Rheumatoid Arthritis

Japan
Bio-Thera Solutions

Completed

Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

Rheumatoid Arthritis

China
AbbVie

Completed

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

Rheumatoid Arthritis

United States, Bulgaria, Chile, Czechia, Hungary, Israel, Latvia, Mexico, Poland, Puerto Rico, Russian Federation, Slovakia, South Africa, Spain, Turkey, Ukraine
Eisai Co., Ltd.

Completed

A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate

Rheumatoid Arthritis

Japan
Gilead Sciences
Galapagos NV

Completed

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (FINCH 1)

Rheumatoid Arthritis

United States, Italy, Poland, Ukraine, Belgium, Hong Kong, Taiwan, Spain, Israel, Bulgaria, India, Serbia, South Africa, Korea, Republic of, Japan, Russian Federation, Argentina, Germany, New Zealand, Thailand, Hungary, Netherlands, Slovaki... and more
SecuraBio

Completed

A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone (ASPIRA)

Rheumatoid Arthritis

Poland, Ukraine, Mexico, Bulgaria, Romania, Serbia, New Zealand, Russian Federation, Germany, Hungary, Colombia
Dartmouth-Hitchcock Medical Center
Mallinckrodt

Terminated

ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

Rheumatoid Arthritis

United States
Genentech, Inc.
Roche Pharma AG

Terminated

A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy (FEATURE)

Rheumatoid Arthritis
Genentech, Inc.

Terminated

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

Rheumatoid Arthritis

United States
Astellas Pharma Inc

Completed

A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment

Rheumatoid Arthritis

Japan
Pfizer

Completed

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate

Rheumatoid Arthritis

United States, Korea, Republic of, Spain, Taiwan, Serbia, Georgia, Australia, Hungary, Czechia, Poland, Mexico, Russian Federation, Bosnia and Herzegovina, Germany, Bulgaria, Croatia, Romania, Slovakia, Ukraine
Hoffmann-La Roche

Terminated

A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy

Rheumatoid Arthritis

Spain, United Kingdom, United States, Italy, Peru, Argentina, Colombia, Mexico, Germany, Austria, Guatemala
Chong Kun Dang Pharmaceutical

Completed

A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate

Rheumatoid Arthritis

Czechia, Georgia, Poland, Russian Federation, Ukraine
Pfizer

Completed

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01) (REFLECTIONS)

Rheumatoid Arthritis

United States, United Kingdom, Australia, Mexico, South Africa, Canada, Colombia, Germany, Israel, Russian Federation
Instituto Nacional de Ciencias Medicas y Nutricion...

Completed

Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response

HIV Infections

Mexico
Astellas Pharma Inc

Completed

A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate

Arthritis, Rheumatoid

United States, Poland, Colombia, Belgium, Czechia, Bulgaria, Hungary, Mexico
RemeGen Co., Ltd.

Terminated

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

Moderate and Severe Rheumatoid Arthritis

China
Takeda

Terminated

Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate (TELLUS)

Rheumatoid Arthritis

Spain, Estonia, Russian Federation, Czechia, United Kingdom
Pfizer

Completed

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Arthritis, Rheumatoid

Australia, United States, Austria, Germany, Ireland, Brazil, Spain, Taiwan, Belgium, Canada, France, Italy, Korea, Republic of, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent (ACT-MOVE)

Rheumatoid Arthritis

United Kingdom
Eli Lilly and Company

Completed

A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

Arthritis, Rheumatoid

United States, Argentina, Germany, Puerto Rico, Mexico, Belgium, Poland, Brazil, Austria, Canada
Pfizer

Completed

Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

Rheumatoid Arthritis

United States, Poland, Serbia, Slovakia, Czechia, Georgia, Germany, Bulgaria, Hungary
AbbVie

Withdrawn

Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate

Rheumatoid Arthritis (RA)

China
Hoffmann-La Roche

Completed

A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy (TOSCA)

Rheumatoid Arthritis

France
Novo Nordisk A/S

Terminated

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Inflammation | Rheumatoid Arthritis

United States, Mexico, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Hungary, Poland, United Kingdom
UCB Pharma SA
Parexel

Completed

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Rheumatoid Arthritis

Romania, United States, Australia, Austria, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Ireland, Italy, Mexico, Monaco, Poland, Portugal, Spain, Switzerland, United Kingdom
Hoffmann-La Roche

Completed

A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Rheumatoid Arthritis

Denmark, Finland, Norway, Sweden
Biotest
AbbVie

Terminated

Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis (986)

Rheumatoid Arthritis

United States, Bulgaria, Canada, Czechia, Estonia, Germany, Hungary, Lithuania, Mexico, Poland, Russian Federation, Serbia, Slovakia, Ukraine

3

Subscribe